FDG-PET for the diagnosis and management of soft tissue sarcoma
Ioannidis JP, Lau J
Record ID 32002000434
English
Authors' objectives:
This report aims to perform an assessment on the use of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in the diagnosis, grading, and management of soft tissue sarcoma (STS).
Authors' results and conclusions:
Twenty studies were included in this systematic review. By qualitative interpretation, the sensitivity of FDG-PET ranged from 91 to 100% and the specificity varied between 26 to 88% in diagnosing primary lesions. When an SUV cut-off of >2.0 was used to evaluate primary lesions, the sensitivity ranged between 64 to 100% and the specificity ranged between 71 to 100%. Diagnostic performance was similar for primary and recurrent lesions. Limited data on comparisons with MRI and CT scan showed no differences between FDG-PET and these imaging modalities in diagnosing recurrent and metastatic disease.
Authors' recommendations:
FDG-PET has very good discriminating ability in the evaluation of both primary and recurrent soft tissue lesions. FDG-PET may be helpful in tumor grading, but offers inadequate discrimination between low-grade tumors and benign lesions. There is insufficient data on the impact of FDG-PET on clinical outcomes and on the usefulness of FDG-PET in assessing the response to therapy.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.cms.gov/coverage/8b3-iii.asp
Year Published:
2002
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Tomography, Emission-Computed
- Fluorodeoxyglucose F18
- Sarcoma
- Soft Tissue Neoplasms
Contact
Organisation Name:
Agency for Healthcare Research and Quality
Contact Address:
The Evidence-based Practice Center (EPC) Program, Center for Evidence and Practice Improvement, 5600 Fishers Lane, Rockville, MD 20857, USA. Tel: +1 301 427 1550
Contact Name:
The EPC Program
Contact Email:
epc@ahrq.hhs.gov
Copyright:
Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.